首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >ASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTSASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTS
【24h】

ASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTSASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTS

机译:代谢综合征患者的亚临床甲状腺功能减退症的关联代谢综合征患者的亚临床甲状腺功能减退症的关联

获取原文
       

摘要

Objectives: Subclinical hypothyroidism (SCH) is also the major risk for cardiovascular disease like metabolic syndrome (MetS). Hence, the aim of this study is to assess the association of SCH in MetS patients. Materials and Methods: Ninety patients reporting to Saveetha Dental College and Hospitals were enrolled in the study which includes 40 patients with MetS and 40 healthy individuals. 5 ml of venous blood was collected and centrifuged. Then, it is analyzed for fasting blood sugar, serum triglycerides, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and very low-density lipoprotein (VLDL) using the standard kit method. Then, Free T3, Free T4, and thyroid-stimulating hormone (TSH) were estimated by ELISA method. The data obtained were subjected to statistical analysis using the SPSS software. Results: SCH is 20% in cases when compared to 4.4% in controls, which was significant, p=0.024. The biochemical parameters were compared between the study population fasting blood glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and VLDL cholesterol was statistically significant, with p0.001. TSH levels showed significant difference between two groups with the p=0.002. Conclusion: MetS patients should be screened for the SCH as an important risk factor in evaluation protocol. Mere correction of TSH levels can reverse the associated morbidity in these patients rather than leaving them untreated pushing them to a state of overt hypothyroidism with its attendant complications.
机译:目的:亚临床甲状腺功能减退症(SCH)也是心血管疾病(如代谢综合征(MetS))的主要风险。因此,本研究的目的是评估MetS患者中SCH的相关性。资料和方法:本研究招募了90位向Saveetha牙科学院和医院报告的患者,其中包括40位MetS患者和40位健康个体。收集5ml静脉血并离心。然后,使用标准试剂盒方法分析空腹血糖,血清甘油三酸酯,高密度脂蛋白胆固醇(HDL-c),低密度脂蛋白胆固醇(LDL-c)和极低密度脂蛋白(VLDL)。然后,通过ELISA方法估算游离T3,游离T4和促甲状腺激素(TSH)。使用SPSS软件对获得的数据进行统计分析。结果:与对照组的4.4%相比,病例的SCH为20%,这是显着的,p = 0.024。比较研究人群的空腹血糖,甘油三酸酯,总胆固醇,低密度脂蛋白胆固醇和VLDL胆固醇的生化参数具有统计学意义,p <0.001。两组之间的TSH水平显示出显着差异,p = 0.002。结论:应筛选MetS患者的SCH作为评估方案中的重要危险因素。仅仅校正TSH水平可以逆转这些患者的相关发病率,而不是不进行治疗就将他们推向明显的甲状腺功能减退症并伴有并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号